Second chances or surgical selection? Interpreting parathyroidectomy outcomes after kidney transplantation

To the Editor, Tertiary hyperparathyroidism remains a common metabolic complication after kidney transplantation, often persisting despite restored renal function and contributing to hypercalcemia, bone disease, nephrocalcinosis, and possible graft dysfunction[1]. Optimizing mineral metabolism is therefore important for long-term graft preservation. In a recent study published in the Journal of the American College of Surgeons, Kasmirski et al[2] compared parathyroidectomy (PTX) with cinacalcet in kidney transplant recipients and reported lower rates of graft failure, dialysis dependence, and renal osteodystrophy among patients undergoing surgery. These findings support the growing view that definitive surgical treatment may provide benefits beyond biochemical control. PTX reliably lowers parathyroid hormone (PTH) levels, corrects hypercalcemia, and may reduce ongoing calcium–phosphate imbalance implicated in vascular and allograft injury[3]. By contrast, cinacalcet can improve laboratory parameters but often requires prolonged therapy, adherence, and continued monitoring, with less certain effects on long-term graft outcomes[4]. In this context, the study raises an important question regarding whether PTX should be considered earlier in selected recipients. However, caution is warranted before attributing the observed benefits solely to surgery. The analysis was retrospective and based on a federated database, which may be affected by coding inaccuracies, missing variables, and residual confounding. Timing of intervention is another key consideration. The interval between transplantation, diagnosis of tertiary hyperparathyroidism, and PTX may significantly affect outcomes. Earlier surgery in recipients with stable graft function may yield different results than delayed intervention in those with evolving chronic allograft dysfunction[3]. Without granular temporal data or serial biochemical trends, including PTH, calcium, phosphate, and estimated glomerular filtration rate, it remains difficult to determine whether PTX altered the disease trajectory or reflected the selection of lower-risk candidates. Nevertheless, the study addresses a clinically important area where practice remains heterogeneous. Many centers vary considerably in thresholds for recommending surgery versus prolonged calcimimetic therapy. While PTX offers durable correction, it also carries perioperative risks such as transient hypocalcemia, recurrent laryngeal nerve injury, and hospitalization[5]. Conversely, delayed treatment of uncontrolled tertiary hyperparathyroidism may expose recipients to avoidable skeletal and renal complications. In light of these considerations, prospective multicenter studies are needed to clarify the optimal timing of PTX, identify recipients most likely to benefit, and compare long-term graft outcomes, quality of life, and cost-effectiveness with contemporary medical therapy. Until such evidence emerges, management should remain individualized, balancing surgical durability against patient comorbidity, graft status, and institutional expertise. The favorable outcomes associated with PTX may indeed represent second chances for some recipients, but the contribution of surgical selection should not be overlooked. This study followed the Transparency in the Reporting of Artificial Intelligence (TITAN) guidelines 2025[6].